Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Multiple Sclerosis
Last updated March 4, 2013
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Thrombotic events in Acute Coronary Syndromes, Prevention
Last updated September 12, 2012
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Advanced Melanoma
Last updated August 28, 2012
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Atrial fibrillation, stroke prevention
Last updated June 19, 2012
Pradaxa (dabigatran etexilate)
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Atrial fibrillation prevention of stroke and systemic embolism
Last updated August 21, 2013